Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$6.74
-0.3%
$6.76
$2.32
$14.84
$479.02M0.083.79 million shs1.66 million shs
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$11.18
-7.3%
$11.57
$4.26
$16.90
$613.93M0.71634,206 shs175,190 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$29.34
-6.8%
$26.70
$14.35
$32.40
$985.41MN/A174,098 shs108,722 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$17.15
-1.5%
$16.87
$6.07
$19.71
$1.02B0.71816,852 shs689,646 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-8.15%+0.60%+10.10%+11.00%+180.50%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
+0.58%+7.01%+9.54%+7.77%+141.68%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+0.80%+4.07%+33.91%+46.37%+3,146,999,900.00%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
+0.81%+6.67%-3.65%+52.41%+87.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.8483 of 5 stars
3.41.00.00.02.02.50.0
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
1.9847 of 5 stars
3.60.00.00.03.81.70.0
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
1.0478 of 5 stars
3.50.00.00.02.20.00.0
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.2655 of 5 stars
3.40.00.00.02.43.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.86
Moderate Buy$18.80178.93% Upside
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.17
Buy$25.20125.40% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
3.00
Buy$36.8025.43% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.75
Moderate Buy$22.5031.20% Upside

Current Analyst Ratings

Latest ATXS, PHAT, AVBP, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/27/2024
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
9/13/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
9/11/2024
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $36.00
9/10/2024
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$35.00 ➝ $39.00
9/10/2024
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $38.00
9/10/2024
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $36.00
9/6/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/30/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/22/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
8/19/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/16/2024
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$25.00 ➝ $30.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$409K1,171.19N/AN/A$2.75 per share2.45
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.33 per shareN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A($4.79) per shareN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$9.92M103.05N/AN/A($1.27) per share-13.50

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.62N/AN/AN/A-24,778.97%-53.09%-48.14%11/5/2024 (Estimated)
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$72.89M-$2.32N/AN/AN/AN/A-49.00%-31.20%11/11/2024 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$69.33MN/A0.00N/AN/AN/AN/AN/A11/13/2024 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$201.59M-$5.13N/AN/AN/AN/AN/A-75.81%11/7/2024 (Confirmed)

Latest ATXS, PHAT, AVBP, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/7/2024N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$1.57N/A+$1.57N/AN/AN/A  
8/14/2024N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.65-$0.65N/A-$0.65N/AN/A
8/12/2024Q2 2024
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.38-$0.43-$0.05-$0.43N/AN/A
8/8/2024Q2 2024
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.34-$0.35-$0.01-$0.35N/A$0.01 million    
8/8/2024Q2 2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$1.39-$1.35+$0.04-$1.14$5.65 million$7.32 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
11.30
11.30
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
21.86
21.87
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
25.50
25.50
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
6.48
6.44

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.90%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
24.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5071.07 million68.16 millionOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3054.91 million54.79 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4033.59 millionN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11059.59 million45.23 millionOptionable

ATXS, PHAT, AVBP, and ALT Headlines

Recent News About These Companies

Needham Sticks to Their Hold Rating for Lexicon Pharmaceuticals (LXRX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Astria Therapeutics logo

Astria Therapeutics

NASDAQ:ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
ArriVent BioPharma logo

ArriVent BioPharma

NASDAQ:AVBP
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Phathom Pharmaceuticals logo

Phathom Pharmaceuticals

NASDAQ:PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.